Maeta M, Koga S, Shimizu N, Osaki Y, Hirai Y, Kato K, Masaki T, Maeta K, Kishimoto H, Watanabe S, Sugihara T, Iwasaki T, Tasaki M, Abe J, Yamashiro N
Gan To Kagaku Ryoho. 1982 Oct;9(10):1742-8.
We have previously reported the clinical effect of NF therapy (NCS 5,000 units and 5-FU 500 mg intravenously; twice a week) on patients with advanced carcinoma of the digestive system. In the present study, NFO therapy (NCS 2,000 units and 5-FU 500 mg intravenously, Picibanil 1-2K. E. intramuscularly; twice a week) was applied for those patients to take advantage over NF modality. Treated were 62 patients with NFO and 48 were evaluated for its clinical effects. In comparison of NFO and NF, the antitumor effects were noted in 9 of 48 patients (18.8%) for NFO, and 2 of 27 (7.4%) for NF therapy judged by Koyama & Saito's criterion. If the Karnofsky's criterion was applied, I-A category or more were obtained in 10 of 48 patients (20.8%) for NFO and in 2 of 27 (7.4%) for NF therapy. In particular, NFO therapy resulted in the advantageous clinical effects on patients with hepatic and pancreatic carcinomas irrespective of primary or metastatic. The adverse effects of NFO were not more frequent than those of NF therapy. From these results, a new combination regimen, NFO, is thought to bring about a considerable benefit in the treatment of advanced carcinoma of the digestive organs.
我们之前已经报道了NF疗法（静脉注射NCS 5000单位和5-氟尿嘧啶500毫克；每周两次）对晚期消化系统癌患者的临床疗效。在本研究中，对这些患者应用了NFO疗法（静脉注射NCS 2000单位和5-氟尿嘧啶500毫克，肌肉注射争光霉素1-2K.E.；每周两次），以使其优于NF疗法。接受NFO治疗的患者有62例，其中48例评估了其临床疗效。比较NFO和NF，根据小山和斋藤的标准判断，NFO治疗的48例患者中有9例（18.8%）出现抗肿瘤效果，NF疗法的27例患者中有2例（7.4%）出现抗肿瘤效果。如果应用卡诺夫斯基标准，NFO治疗的48例患者中有10例（20.8%）获得I-A级或更高等级，NF疗法的27例患者中有2例（7.4%）获得该等级。特别是，NFO疗法对原发性或转移性肝癌和胰腺癌患者均产生了有利的临床效果。NFO的不良反应并不比NF疗法更频繁。从这些结果来看，一种新的联合方案NFO被认为在晚期消化器官癌的治疗中能带来相当大的益处。
